Health-related quality of life results from the phase III CheckMate 067 study.
Identifieur interne : 000B09 ( PubMed/Checkpoint ); précédent : 000B08; suivant : 000B10Health-related quality of life results from the phase III CheckMate 067 study.
Auteurs : Dirk Schadendorf [Allemagne] ; James Larkin [Royaume-Uni] ; Jedd Wolchok [États-Unis] ; F Stephen Hodi [États-Unis] ; Vanna Chiarion-Sileni [Italie] ; Rene Gonzalez [États-Unis] ; Piotr Rutkowski [Pologne] ; Jean-Jacques Grob [France] ; C Lance Cowey [États-Unis] ; Christopher Lao [États-Unis] ; John Wagstaff [Royaume-Uni] ; Margaret K. Callahan [États-Unis] ; Michael A. Postow [États-Unis] ; Michael Smylie [Canada] ; Pier Francesco Ferrucci [Italie] ; Reinhard Dummer [Suisse] ; Andrew Hill [Australie] ; Fiona Taylor [États-Unis] ; Javier Sabater [États-Unis] ; Dana Walker [États-Unis] ; Srividya Kotapati [États-Unis] ; Amy Abernethy [États-Unis] ; Georgina V. Long [Australie]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux (administration et posologie), Anticorps monoclonaux (usage thérapeutique), Antinéoplasiques (usage thérapeutique), Femelle, Humains, Mâle, Mélanome (traitement médicamenteux), Méthode en double aveugle, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Qualité de vie, Sujet âgé, État de santé.
- MESH :
- administration et posologie : Anticorps monoclonaux.
- traitement médicamenteux : Mélanome.
- usage thérapeutique : Anticorps monoclonaux, Antinéoplasiques, Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mâle, Méthode en double aveugle, Qualité de vie, Sujet âgé, État de santé.
English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (therapeutic use), Antineoplastic Agents (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Double-Blind Method, Female, Health Status, Humans, Male, Melanoma (drug therapy), Middle Aged, Quality of Life.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal.
- chemical , therapeutic use : Antibodies, Monoclonal, Antineoplastic Agents.
- drug therapy : Melanoma.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Double-Blind Method, Female, Health Status, Humans, Male, Middle Aged, Quality of Life.
Abstract
Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.
DOI: 10.1016/j.ejca.2017.05.031
PubMed: 28651159
Affiliations:
- Allemagne, Australie, Canada, France, Italie, Pologne, Royaume-Uni, Suisse, États-Unis
- Angleterre, Bade-Wurtemberg, Canton de Zurich, Caroline du Nord, Colorado, District de Karlsruhe, Grand Londres, Lombardie, Massachusetts, Michigan, New Jersey, Nouvelle-Galles du Sud, Provence-Alpes-Côte d'Azur, Texas, État de New York
- Heidelberg, Londres, Marseille, Milan, Sydney, Zurich
- Université de Sydney, Université de Zurich
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28651159Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Health-related quality of life results from the phase III CheckMate 067 study.</title><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University of Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University of Essen, Essen, Germany; German Cancer Consortium, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation wicri:level="3"><nlm:affiliation>Royal Marsden Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Wolchok, Jedd" sort="Wolchok, Jedd" uniqKey="Wolchok J" first="Jedd" last="Wolchok">Jedd Wolchok</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name><affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name><affiliation wicri:level="1"><nlm:affiliation>Istituto Oncologico Veneto, Veneto, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Oncologico Veneto, Veneto</wicri:regionArea><wicri:noRegion>Veneto</wicri:noRegion></affiliation></author><author><name sortKey="Gonzalez, Rene" sort="Gonzalez, Rene" uniqKey="Gonzalez R" first="Rene" last="Gonzalez">Rene Gonzalez</name><affiliation wicri:level="2"><nlm:affiliation>University of Colorado, Denver, CO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Colorado, Denver, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name><affiliation wicri:level="1"><nlm:affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="3"><nlm:affiliation>Hospital de la Timone, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hospital de la Timone, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Cowey, C Lance" sort="Cowey, C Lance" uniqKey="Cowey C" first="C Lance" last="Cowey">C Lance Cowey</name><affiliation wicri:level="2"><nlm:affiliation>Texas Oncology-Baylor Cancer Center, Dallas, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Oncology-Baylor Cancer Center, Dallas, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Lao, Christopher" sort="Lao, Christopher" uniqKey="Lao C" first="Christopher" last="Lao">Christopher Lao</name><affiliation wicri:level="2"><nlm:affiliation>University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Wagstaff, John" sort="Wagstaff, John" uniqKey="Wagstaff J" first="John" last="Wagstaff">John Wagstaff</name><affiliation wicri:level="1"><nlm:affiliation>The College of Medicine, Swansea University, Swansea, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The College of Medicine, Swansea University, Swansea</wicri:regionArea><wicri:noRegion>Swansea</wicri:noRegion></affiliation></author><author><name sortKey="Callahan, Margaret K" sort="Callahan, Margaret K" uniqKey="Callahan M" first="Margaret K" last="Callahan">Margaret K. Callahan</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Postow, Michael A" sort="Postow, Michael A" uniqKey="Postow M" first="Michael A" last="Postow">Michael A. Postow</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Smylie, Michael" sort="Smylie, Michael" uniqKey="Smylie M" first="Michael" last="Smylie">Michael Smylie</name><affiliation wicri:level="1"><nlm:affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Cross Cancer Institute, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Ferrucci, Pier Francesco" sort="Ferrucci, Pier Francesco" uniqKey="Ferrucci P" first="Pier Francesco" last="Ferrucci">Pier Francesco Ferrucci</name><affiliation wicri:level="3"><nlm:affiliation>Istituto Europeo di Oncologia, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Europeo di Oncologia, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name><affiliation wicri:level="4"><nlm:affiliation>University of Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University of Zurich, Zurich</wicri:regionArea><orgName type="university">Université de Zurich</orgName><placeName><settlement type="city">Zurich</settlement><region nuts="3" type="region">Canton de Zurich</region></placeName></affiliation></author><author><name sortKey="Hill, Andrew" sort="Hill, Andrew" uniqKey="Hill A" first="Andrew" last="Hill">Andrew Hill</name><affiliation wicri:level="1"><nlm:affiliation>Tasman Oncology Research, Brisbane, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Tasman Oncology Research, Brisbane, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Taylor, Fiona" sort="Taylor, Fiona" uniqKey="Taylor F" first="Fiona" last="Taylor">Fiona Taylor</name><affiliation wicri:level="2"><nlm:affiliation>Adelphi Values, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Adelphi Values, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Sabater, Javier" sort="Sabater, Javier" uniqKey="Sabater J" first="Javier" last="Sabater">Javier Sabater</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Walker, Dana" sort="Walker, Dana" uniqKey="Walker D" first="Dana" last="Walker">Dana Walker</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kotapati, Srividya" sort="Kotapati, Srividya" uniqKey="Kotapati S" first="Srividya" last="Kotapati">Srividya Kotapati</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Abernethy, Amy" sort="Abernethy, Amy" uniqKey="Abernethy A" first="Amy" last="Abernethy">Amy Abernethy</name><affiliation wicri:level="2"><nlm:affiliation>Duke University Medical Center, Durham, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="4"><nlm:affiliation>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28651159</idno><idno type="pmid">28651159</idno><idno type="doi">10.1016/j.ejca.2017.05.031</idno><idno type="wicri:Area/PubMed/Corpus">000640</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000640</idno><idno type="wicri:Area/PubMed/Curation">000638</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000638</idno><idno type="wicri:Area/PubMed/Checkpoint">000638</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000638</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Health-related quality of life results from the phase III CheckMate 067 study.</title><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University of Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University of Essen, Essen, Germany; German Cancer Consortium, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation wicri:level="3"><nlm:affiliation>Royal Marsden Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Wolchok, Jedd" sort="Wolchok, Jedd" uniqKey="Wolchok J" first="Jedd" last="Wolchok">Jedd Wolchok</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name><affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name><affiliation wicri:level="1"><nlm:affiliation>Istituto Oncologico Veneto, Veneto, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Oncologico Veneto, Veneto</wicri:regionArea><wicri:noRegion>Veneto</wicri:noRegion></affiliation></author><author><name sortKey="Gonzalez, Rene" sort="Gonzalez, Rene" uniqKey="Gonzalez R" first="Rene" last="Gonzalez">Rene Gonzalez</name><affiliation wicri:level="2"><nlm:affiliation>University of Colorado, Denver, CO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Colorado, Denver, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name><affiliation wicri:level="1"><nlm:affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="3"><nlm:affiliation>Hospital de la Timone, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hospital de la Timone, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Cowey, C Lance" sort="Cowey, C Lance" uniqKey="Cowey C" first="C Lance" last="Cowey">C Lance Cowey</name><affiliation wicri:level="2"><nlm:affiliation>Texas Oncology-Baylor Cancer Center, Dallas, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Oncology-Baylor Cancer Center, Dallas, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Lao, Christopher" sort="Lao, Christopher" uniqKey="Lao C" first="Christopher" last="Lao">Christopher Lao</name><affiliation wicri:level="2"><nlm:affiliation>University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Wagstaff, John" sort="Wagstaff, John" uniqKey="Wagstaff J" first="John" last="Wagstaff">John Wagstaff</name><affiliation wicri:level="1"><nlm:affiliation>The College of Medicine, Swansea University, Swansea, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The College of Medicine, Swansea University, Swansea</wicri:regionArea><wicri:noRegion>Swansea</wicri:noRegion></affiliation></author><author><name sortKey="Callahan, Margaret K" sort="Callahan, Margaret K" uniqKey="Callahan M" first="Margaret K" last="Callahan">Margaret K. Callahan</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Postow, Michael A" sort="Postow, Michael A" uniqKey="Postow M" first="Michael A" last="Postow">Michael A. Postow</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Smylie, Michael" sort="Smylie, Michael" uniqKey="Smylie M" first="Michael" last="Smylie">Michael Smylie</name><affiliation wicri:level="1"><nlm:affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Cross Cancer Institute, Edmonton, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Ferrucci, Pier Francesco" sort="Ferrucci, Pier Francesco" uniqKey="Ferrucci P" first="Pier Francesco" last="Ferrucci">Pier Francesco Ferrucci</name><affiliation wicri:level="3"><nlm:affiliation>Istituto Europeo di Oncologia, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Europeo di Oncologia, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name><affiliation wicri:level="4"><nlm:affiliation>University of Zurich, Zurich, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>University of Zurich, Zurich</wicri:regionArea><orgName type="university">Université de Zurich</orgName><placeName><settlement type="city">Zurich</settlement><region nuts="3" type="region">Canton de Zurich</region></placeName></affiliation></author><author><name sortKey="Hill, Andrew" sort="Hill, Andrew" uniqKey="Hill A" first="Andrew" last="Hill">Andrew Hill</name><affiliation wicri:level="1"><nlm:affiliation>Tasman Oncology Research, Brisbane, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Tasman Oncology Research, Brisbane, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Taylor, Fiona" sort="Taylor, Fiona" uniqKey="Taylor F" first="Fiona" last="Taylor">Fiona Taylor</name><affiliation wicri:level="2"><nlm:affiliation>Adelphi Values, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Adelphi Values, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Sabater, Javier" sort="Sabater, Javier" uniqKey="Sabater J" first="Javier" last="Sabater">Javier Sabater</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Walker, Dana" sort="Walker, Dana" uniqKey="Walker D" first="Dana" last="Walker">Dana Walker</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kotapati, Srividya" sort="Kotapati, Srividya" uniqKey="Kotapati S" first="Srividya" last="Kotapati">Srividya Kotapati</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Abernethy, Amy" sort="Abernethy, Amy" uniqKey="Abernethy A" first="Amy" last="Abernethy">Amy Abernethy</name><affiliation wicri:level="2"><nlm:affiliation>Duke University Medical Center, Durham, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="4"><nlm:affiliation>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Health Status</term><term>Humans</term><term>Male</term><term>Melanoma (drug therapy)</term><term>Middle Aged</term><term>Quality of Life</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (administration et posologie)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Mélanome (traitement médicamenteux)</term><term>Méthode en double aveugle</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Qualité de vie</term><term>Sujet âgé</term><term>État de santé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Antinéoplasiques</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Health Status</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Qualité de vie</term><term>Sujet âgé</term><term>État de santé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28651159</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>26</Day></DateCreated><DateCompleted><Year>2017</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Health-related quality of life results from the phase III CheckMate 067 study.</ArticleTitle><Pagination><MedlinePgn>80-91</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(17)30995-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2017.05.031</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">HRQoL was assessed at weeks 1 and 5 per 6-week cycle for the first 6 months, once every 6 weeks thereafter, and at two follow-up visits using the European Organization for Research and Treatment of Care Core Quality of Life Questionnaire and the EuroQoL Five Dimensions Questionnaire. In addition to the randomised population, patient subgroups, including BRAF mutation status, partial or complete response, treatment-related AEs of grade 3/4, and those who discontinued due to any reason and due to an AE, were investigated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nivolumab and ipilimumab combination and nivolumab alone both maintained HRQoL, and no clinically meaningful deterioration was observed over time compared with ipilimumab. In addition, similar results were observed across patient subgroups, and no clinically meaningful changes in HRQoL were observed during follow-up visits for patients who discontinued due to any cause.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results further support the clinical benefit of nivolumab monotherapy and nivolumab and ipilimumab combination therapy in patients with advanced melanoma. The finding that the difference in grade 3/4 AEs between the arms did not translate into clinically meaningful differences in the reported HRQoL may be relevant in the clinical setting.</AbstractText><AbstractText Label="STUDY NUMBER" NlmCategory="UNASSIGNED">NCT01844505.</AbstractText><CopyrightInformation>Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schadendorf</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larkin</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Royal Marsden Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolchok</LastName><ForeName>Jedd</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodi</LastName><ForeName>F Stephen</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiarion-Sileni</LastName><ForeName>Vanna</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Istituto Oncologico Veneto, Veneto, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Rene</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Colorado, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutkowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grob</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Hospital de la Timone, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowey</LastName><ForeName>C Lance</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Texas Oncology-Baylor Cancer Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lao</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagstaff</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The College of Medicine, Swansea University, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Margaret K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postow</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smylie</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Pier Francesco</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Istituto Europeo di Oncologia, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dummer</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tasman Oncology Research, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Adelphi Values, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabater</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotapati</LastName><ForeName>Srividya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abernethy</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Duke University Medical Center, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Georgina V</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>31YO63LBSN</RegistryNumber><NameOfSubstance UI="C581771">nivolumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T8C155666</RegistryNumber><NameOfSubstance UI="C508317">ipilimumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Advanced melanoma</Keyword><Keyword MajorTopicYN="N">Checkpoint inhibitors</Keyword><Keyword MajorTopicYN="N">Health-related quality of life</Keyword><Keyword MajorTopicYN="N">Ipilimumab</Keyword><Keyword MajorTopicYN="N">Nivolumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28651159</ArticleId><ArticleId IdType="pii">S0959-8049(17)30995-4</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2017.05.031</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>France</li><li>Italie</li><li>Pologne</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Bade-Wurtemberg</li><li>Canton de Zurich</li><li>Caroline du Nord</li><li>Colorado</li><li>District de Karlsruhe</li><li>Grand Londres</li><li>Lombardie</li><li>Massachusetts</li><li>Michigan</li><li>New Jersey</li><li>Nouvelle-Galles du Sud</li><li>Provence-Alpes-Côte d'Azur</li><li>Texas</li><li>État de New York</li></region><settlement><li>Heidelberg</li><li>Londres</li><li>Marseille</li><li>Milan</li><li>Sydney</li><li>Zurich</li></settlement><orgName><li>Université de Sydney</li><li>Université de Zurich</li></orgName></list><tree><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name></region><name sortKey="Wagstaff, John" sort="Wagstaff, John" uniqKey="Wagstaff J" first="John" last="Wagstaff">John Wagstaff</name></country><country name="États-Unis"><region name="État de New York"><name sortKey="Wolchok, Jedd" sort="Wolchok, Jedd" uniqKey="Wolchok J" first="Jedd" last="Wolchok">Jedd Wolchok</name></region><name sortKey="Abernethy, Amy" sort="Abernethy, Amy" uniqKey="Abernethy A" first="Amy" last="Abernethy">Amy Abernethy</name><name sortKey="Callahan, Margaret K" sort="Callahan, Margaret K" uniqKey="Callahan M" first="Margaret K" last="Callahan">Margaret K. Callahan</name><name sortKey="Cowey, C Lance" sort="Cowey, C Lance" uniqKey="Cowey C" first="C Lance" last="Cowey">C Lance Cowey</name><name sortKey="Gonzalez, Rene" sort="Gonzalez, Rene" uniqKey="Gonzalez R" first="Rene" last="Gonzalez">Rene Gonzalez</name><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name><name sortKey="Kotapati, Srividya" sort="Kotapati, Srividya" uniqKey="Kotapati S" first="Srividya" last="Kotapati">Srividya Kotapati</name><name sortKey="Lao, Christopher" sort="Lao, Christopher" uniqKey="Lao C" first="Christopher" last="Lao">Christopher Lao</name><name sortKey="Postow, Michael A" sort="Postow, Michael A" uniqKey="Postow M" first="Michael A" last="Postow">Michael A. Postow</name><name sortKey="Sabater, Javier" sort="Sabater, Javier" uniqKey="Sabater J" first="Javier" last="Sabater">Javier Sabater</name><name sortKey="Taylor, Fiona" sort="Taylor, Fiona" uniqKey="Taylor F" first="Fiona" last="Taylor">Fiona Taylor</name><name sortKey="Walker, Dana" sort="Walker, Dana" uniqKey="Walker D" first="Dana" last="Walker">Dana Walker</name></country><country name="Italie"><noRegion><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name></noRegion><name sortKey="Ferrucci, Pier Francesco" sort="Ferrucci, Pier Francesco" uniqKey="Ferrucci P" first="Pier Francesco" last="Ferrucci">Pier Francesco Ferrucci</name></country><country name="Pologne"><noRegion><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name></noRegion></country><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name></region></country><country name="Canada"><noRegion><name sortKey="Smylie, Michael" sort="Smylie, Michael" uniqKey="Smylie M" first="Michael" last="Smylie">Michael Smylie</name></noRegion></country><country name="Suisse"><region name="Canton de Zurich"><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name></region></country><country name="Australie"><noRegion><name sortKey="Hill, Andrew" sort="Hill, Andrew" uniqKey="Hill A" first="Andrew" last="Hill">Andrew Hill</name></noRegion><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B09 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000B09 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28651159
|texte= Health-related quality of life results from the phase III CheckMate 067 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28651159" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |